Diabetes Insipidus and Copeptin

An educational clinical biochemistry article on AVP deficiency, AVP resistance, copeptin testing, osmolality and patient safety in water balance disorders.

Diabetes insipidus is a rare disorder of water balance. It is different from diabetes mellitus and is not caused by high blood glucose.

This article explains the condition in a laboratory medicine context and introduces copeptin as a useful marker in specialist endocrine assessment. It is educational only and does not replace clinical guidance, local protocols or specialist medical advice.

Who this guide is for

This article is useful if you are:

A Biomedical Science student.
A trainee or registered Biomedical Scientist.
Interested in clinical biochemistry or endocrinology.
Learning about osmolality, sodium and water balance.
Reviewing CPD from an endocrine or pathology teaching session.

Key points

Diabetes insipidus is increasingly described using the terms AVP deficiency and AVP resistance.
It is different from diabetes mellitus.
The condition can cause polyuria, polydipsia and risk of hypernatraemia.
Copeptin is a more stable surrogate marker related to arginine vasopressin release.
Diagnostic testing should be performed under specialist clinical protocols.

Why the name is changing

The term diabetes insipidus can be confused with diabetes mellitus. This matters because the two conditions are very different.

Diabetes mellitus is linked to glucose metabolism and high blood glucose. Diabetes insipidus is linked to water balance and arginine vasopressin function.

To reduce confusion and improve patient safety, many endocrine organisations now support clearer terminology:

Arginine vasopressin deficiency, often shortened to AVP-D, for central or cranial causes.
Arginine vasopressin resistance, often shortened to AVP-R, for nephrogenic causes.

The older term diabetes insipidus is still widely used, so both terms may appear in clinical information, laboratory requests and teaching resources.

Why patient safety matters

Patients with AVP deficiency may require desmopressin and careful fluid management. Missed or delayed treatment can lead to serious dehydration and hypernatraemia.

NHS England has previously issued a patient safety alert about the risk of severe harm or death when desmopressin is omitted or delayed in patients with cranial diabetes insipidus.

For laboratory staff, this reinforces the importance of:

Recognising urgent sodium abnormalities.
Following local escalation procedures.
Understanding why accurate sample timing and documentation matter.
Communicating clearly with clinical teams when required.

How the body controls water balance

Arginine vasopressin, also known as AVP or antidiuretic hormone, helps the body regulate water balance.

AVP is released in response to changes such as rising plasma osmolality or reduced circulating volume. It acts mainly on the kidneys to help conserve water.

The laboratory is often involved through tests such as:

Serum sodium.
Plasma osmolality.
Urine osmolality.
Urine volume assessment.
Paired blood and urine samples.
Specialist endocrine markers where available.

These results must be interpreted alongside clinical assessment.

Main clinical patterns

Polyuria and polydipsia can have several causes. In specialist assessment, clinicians may consider:

AVP deficiency, where there is reduced production or release of AVP.
AVP resistance, where the kidneys do not respond properly to AVP.
Primary polydipsia, where excessive fluid intake suppresses AVP and produces dilute urine.

These conditions can overlap in presentation, which is why careful investigation is needed.

Traditional diagnostic approach

Historically, the water deprivation test has been used to assess the body's ability to concentrate urine when fluids are restricted.

This type of test requires careful clinical supervision because it may involve fluid restriction, repeated sampling and monitoring of weight, urine output, osmolality and sodium.

Laboratory staff may support the pathway by ensuring:

Correct sample type and timing.
Prompt processing where required.
Accurate osmolality measurement.
Clear communication of urgent results.
Documentation in line with local procedures.

These tests should never be treated as routine unsupervised investigations.

What copeptin is

Copeptin is part of the same precursor molecule as arginine vasopressin. It is released into the blood in relation to AVP release.

AVP itself is difficult to measure because it is unstable and technically challenging. Copeptin is more stable, which makes it useful as an indirect marker in specialist assessment.

In clinical biochemistry, copeptin can help support the differentiation of AVP-related disorders when used with the correct clinical pathway.

How copeptin may support diagnosis

Specialist pathways may use copeptin measurement at baseline or after stimulation tests. Some protocols use hypertonic saline or arginine stimulation under controlled conditions.

The aim is to help distinguish between AVP deficiency, AVP resistance and primary polydipsia.

Exact cut-offs, stimulation methods and interpretation rules depend on the protocol, assay and current specialist guidance. Laboratories should follow validated local procedures and refer to current endocrine guidance.

For educational purposes, the key concept is simple: copeptin is more stable than AVP and can provide useful information about AVP system activity.

Laboratory considerations

Introducing or supporting copeptin testing may involve several laboratory considerations:

Assay availability.
Sample type and stability.
Turnaround time.
Quality control and external quality assessment where available.
Reference intervals or decision limits linked to the method.
Clinical governance around stimulated testing.
Communication between laboratory and endocrine teams.

Biomedical Scientists should avoid interpreting specialist endocrine results outside agreed reporting pathways.

CPD reflection points

This topic is useful for CPD because it links physiology, clinical risk and laboratory testing.

Reflection questions include:

How does your laboratory handle urgent sodium results?
What is the role of osmolality testing in your department?
How are specialist endocrine tests requested and reported locally?
What safeguards exist for sample timing and patient identification?
How would you explain the difference between diabetes mellitus and AVP deficiency to a trainee?

CPD reflection should be based on your own learning and workplace context.

Common mistakes to avoid

Common mistakes include:

Confusing diabetes insipidus with diabetes mellitus.
Treating desmopressin delay as a minor issue.
Quoting diagnostic cut-offs without checking the assay and protocol.
Forgetting that water deprivation or stimulation tests require specialist supervision.
Interpreting sodium, osmolality or copeptin results without clinical context.
Using old terminology without recognising the newer AVP-D and AVP-R terms.

Clear terminology and safe escalation are important parts of laboratory practice.

Summary

Diabetes insipidus is a disorder of water balance and is increasingly described as AVP deficiency or AVP resistance. It is clinically important because delayed recognition or treatment can cause serious harm.

Copeptin is an important laboratory marker because it is more stable than AVP and can support specialist diagnostic pathways. For Biomedical Scientists, the key learning is to understand the physiology, respect local protocols and recognise the patient safety implications of sodium and osmolality results.